87.09 -0.37 (-0.42%)
After hours: 4:48PM EST
|Bid||85.00 x 800|
|Ask||92.47 x 900|
|Day's Range||85.64 - 87.91|
|52 Week Range||85.56 - 116.49|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||14.12|
|Earnings Date||Jan 30, 2019 - Feb 4, 2019|
|Forward Dividend & Yield||2.12 (2.42%)|
|1y Target Est||100.75|
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Carl Icahn and George Soros think. Those hedge fund operators make billions of dollars each […]
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
Steve Rusckowski has been the CEO of Quest Diagnostics Incorporated (NYSE:DGX) since 2012. First, this article will compare CEO compensation with compensation at other large companies. Then we'll look at Read More...
SECAUCUS, N.J., Dec. 4, 2018 /PRNewswire/ -- Nearly 80 percent of hospital executives surveyed are not at all familiar, or only somewhat familiar, with the Protecting Access to Medicare Act (PAMA) and its impact on hospitals, according to a survey conducted by Modern Healthcare Custom Media on behalf of Quest Diagnostics (DGX), the world's leading provider of diagnostic information services. "The data presented here support what we've experienced in the health care marketplace," said Steve Rusckowski, Chairman, President and CEO of Quest Diagnostics. "Many C-suite executives of hospital health systems aren't aware of the impact of PAMA on the profitability of their outreach laboratories, especially when the PAMA cuts were first enacted.
Pilot Launched in April under Leadership of Humana, MultiPlan, Optum, Quest Diagnostics and UnitedHealthcare
Investing.com - The Dow snapped a three-day winning streak Thursday, pressured by selling moments before the close, even as minutes from the Fed's November meeting fueled expectations for a slower pace of rate hikes.
The Dow Jones Industrial Average slipped 0.1% to 25,338.84. Investors largely yawned at the release of the November FOMC minutes Thursday afternoon.
The medical lab operator cut its forecasts and said it expects testing volumes to decrease. The information technology products company's forecasts for the current quarter were stronger than analysts expected. The clothing and accessories chain said sales in November have been weak and lowered its annual forecasts.
Shares of Quest Diagnostics Inc. fell more than 4% in the extended session Wednesday after the lab-test company cut its revenue forecast for 2018. Quest said it expects revenue around $7.57 billion for the full year, from previous expectations of revenue around $7.62 billion. Adjusted per-share earnings were seen above $6.30, compared with a previous forecast of adjusted EPS between $6.53 and $6.60 for the year. Quest pinned the downward revisions to increases in its reserves as well as "volume softness" in part due to natural disasters such as Hurricane Michael in the Southeast U.S. and the California wildfires. In the same statement, the company said its board has authorized an increase in the company's quarterly dividend to 53 cents a share from 50 cents a share. The dividend is payable Jan. 30 to shareholders of record as of Jan. 15. Quest shares ended the regular trading day up 2.4%.
Reported diluted EPS now expected to be greater than $5.34 and adjusted diluted EPS excluding amortization expense now expected to be greater than $6.30. SECAUCUS, N.J., Nov. 28, 2018 /PRNewswire/ -- At a meeting with analysts and investors at its Investor Day tomorrow, members of the senior management team of Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, will discuss the company's two-point strategy and range of initiatives underway to accelerate growth and drive operational excellence, and also will outline its near-and long-term financial outlook.
Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.
SECAUCUS, N.J., Nov. 28, 2018 /PRNewswire/ -- Quest Diagnostics Incorporated (DGX), the world's leading provider of diagnostic information services, announced today that it will build a flagship laboratory in Clifton, N.J. to enhance the diagnostic information services it provides to over 40 million people in New Jersey, New York, Pennsylvania, Maryland, Virginia, West Virginia, Delaware and the District of Columbia. The ON3 campus, and its vision to become a mixed-use new-urbanist hub, is attracting forward thinking, innovative and market leading companies. ON3 is home to the Seton Hall-Hackensack Meridian Graduate School of Medicine, and Seton Hall's College of Nursing and School of Health and Medical Sciences.
Quest Diagnostics (DGX) is an American clinical laboratory specializing the provision of diagnostic testing services for cancer, cardiovascular disorders, infectious diseases and neurological disorders. Warning! GuruFocus has detected 2 Warning Signs with HIBB. Quest Diagnostics has a market capitalization of $12.8 billion and is currently trading at $94 per share.
SECAUCUS, N.J. and COLUMBIA, Mo., Nov. 27, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to acquire the assets of the clinical laboratory services business of Boyce and Bynum Pathology Laboratories (BBPL), a leading provider of diagnostic and clinical laboratory services in the Midwest. BBPL's anatomic pathology division, Boyce and Bynum Pathology Professional Services, Inc. (BBPPS), and long-term care division are not part of the transaction.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Building up an investment case requires looking at a stock holistically. Today I’ve chosen to put the spotlight on Quest Diagnostics Incorporated (NYSE:DGX) due to its excellent fundamentals in more Read More...